pubmed.ncbi.nlm.nih.gov

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans - PubMed

Clinical Trial

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans

Marcela V Maus et al. Cancer Immunol Res. 2013 Jul.

Abstract

T cells can be redirected to overcome tolerance to cancer by engineering with integrating vectors to express a chimeric antigen receptor (CAR). In preclinical models, we have previously shown that transfection of T cells with mRNA coding for a CAR is an alternative strategy that has antitumor efficacy and the potential to evaluate the on-target off-tumor toxicity of new CAR targets safely due to transient mRNA CAR expression. Here, we report the safety observed in four patients treated with autologous T cells that had been electroporated with mRNA coding for a CAR derived from a murine antibody to human mesothelin. Because of the transient nature of CAR expression on the T cells, subjects in the clinical study were given repeated infusions of the CAR-T cells to assess their safety. One subject developed anaphylaxis and cardiac arrest within minutes of completing the third infusion. Although human anti-mouse immunoglobulin (Ig)G antibodies have been known to develop with CAR-transduced T cells, they have been thought to have no adverse clinical consequences. This is the first description of clinical anaphylaxis resulting from CAR-modified T cells, most likely through IgE antibodies specific to the CAR. These results indicate that the potential immunogenicity of CARs derived from murine antibodies may be a safety issue for mRNA CARs, especially when administered using an intermittent dosing schedule.

Trial registration: ClinicalTrials.gov NCT01355965.

©2013 AACR.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest

Some authors have intellectual property for chimeric antigen receptor technology (BLL, YZ, CHJ and MK). The other authors have no conflict.

Figures

Figure 1
Figure 1. Clinical trial schema

The subject was originally enrolled onto cohort 1, where 108 meso-RNA-CART cells were administered on Day 0 and 109 meso RNA CART cells were administered on Day 7. Safety assessments were performed between days 0 and 7, and repeat staging was performed by CT scan on day 35. The subject was then enrolled into an extended cohort to receive an additional 6 doses of T cells that were scheduled for Monday/Wednesday/Friday for two weeks. However, the subject developed anaphylaxis immediately after the 3rd infusion (i.e. the first of Extended Cohort 1), and therefore, did not receive any further infusions (marked with an ‘X’).

Figure 2
Figure 2

Serum tryptase in blood. Peripheral blood serum samples at baseline and several time points after the SAE were analyzed for levels of serum tryptase. The dashed line indicates the upper limit of normal range (0.4 – 10.9 μg/L).

Figure 3
Figure 3

(A) Serum cytokines. Peripheral blood serum samples obtained at baseline and from several time points after the event were analyzed for levels of 30 cytokines. Only cytokines elevated at least 1.5-fold over baseline are shown. IL-6 levels at 1 hour after infusion were above the limit of quantification of the assay. (B) Pleural fluid cytokines. The subject had a pleurex catheter in place and pleural fluid was collected 24 hours after the event and periodically thereafter. The levels of 30 cytokines were measured but only the four that were elevated at least 1.5-fold above baseline are shown. IL-6 levels 24 hours after the event were above the limit of quantification of the assay.

Similar articles

Cited by

References

    1. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114:1774–81. - PMC - PubMed
    1. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12:6106–15. - PMC - PubMed
    1. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–71. - PMC - PubMed
    1. Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010;16:5852–61. - PMC - PubMed
    1. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer research. 1992;52:181–6. - PubMed

Publication types

MeSH terms

Substances